# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-01T09:41:45.867405

---

**Idea Fidelity**

The paper largely follows the original idea manifest: it uses the July 2023 PPEO activation in AZ/CA/NV/TX as a quasi-experiment, relies on PECOS and CMS quality data, and focuses on how enhanced entry scrutiny reshapes for-profit hospice entry and related spending/quality metrics. The core identification strategy—a DiD comparing treated states to the rest of the United States with validation via event studies, randomization inference, and wild-cluster bootstrap—is faithfully implemented. One deviation worth highlighting is that the paper stops short of incorporating the December 2025 Wave 2 expansion (GA/OH) as an additional validation check or extension; collecting and analyzing that data would strengthen the original plan’s out-of-sample test.

---

**Summary**

The paper provides the first causal evidence that CMS’s Provisional Period of Enhanced Oversight (PPEO) sharply reduced new hospice enrollments in the four concentrated treatment states, with an 80 percent decline driven almost entirely by for-profit entrants. Using a state-quarter DiD, event studies, and few-cluster inference, the author shows that PPEO selectively screens out for-profit providers without affecting nonprofit entry, consistent with CMS’s fraud-prevention objectives. The compositional shifts align with cross-sectional quality differences—treated states have lower Hospice Care Index scores and fewer visits near death—suggesting that the policy was targeted at markets with low-quality entrants.

---

**Essential Points**

1. **Parallel trends & the California confound:** California had a state-level moratorium from January 2022, so it is both a treated state and one subject to a policy change well before July 2023. The DiD approach compares AZ/CA/NV/TX to all other states, but unless the moratorium is fully accounted for, the estimated treatment effect may conflate PPEO with the earlier CA policy. Even though Table 3 drops CA, the resulting attenuation raises the possibility that pre-existing state-level dynamics drive part of the baseline estimate. The paper needs to better isolate the PPEO effect, perhaps by instrumenting for federal PPEO conditional on pre-existing CA trends, using a stacked DiD that excludes CA from both treatment and controls and/or including CA-specific time trends to test robustness.

2. **Displacement and spillovers:** The paper interprets the decline in treated states solely as a deterrence of poor-quality entry. Yet the deterrence argument requires ruling out (or at least discussing) displacement effects, namely that the same entry was simply redirected to untreated states where PPEO was not active (or ramped up later). Without evidence on neighboring states or on provider destinations, it is hard to distinguish screening from relocation. The wave-2 expansion (GA/OH) offers an ideal placebo/validation moment: do GA/OH show similar drops when PPEO arrives, and do untreated spillover states show corresponding increases? At minimum, the paper should present evidence that enrollments in “frontier” states did not increase post-2023, or that firms subject to PPEO did not refile elsewhere.

3. **Interpretation of outcomes and welfare:** The paper claims that PPEO’s effect “revealed a screening mechanism” that disproportionately deterred fraud-prone, for-profit entry. However, the evidence hinges on compositional changes and denial rates from CMS, not on direct measures of fraud or beneficiary outcomes. The welfare implications therefore rest on unobserved counterfactual quality. To avoid overstating claims, the paper should more carefully bound the interpretation—e.g., conduct back-of-the-envelope calculations of how much high-denial-rate entry would need to be fraudulent to rationalize the observed drop—or use additional outcomes (claims denial, spending on hospice services, patient mix) to triangulate whether the deterred entrants were low-quality rather than merely low-margin.

If these points are not adequately addressed, the paper may overstate the precision of its identification and the policy-relevance of its conclusions.

---

**Suggestions**

1. **Leverage the Wave-2 expansion (GA/OH) for dynamic validation.** The manifest mentioned a December 2025 PPEO extension. Even if full post-treatment data are limited, the paper could exploit the staggered rollout by (a) showing that GA and OH’s pre-DEC2025 trends mirrored the rest of the non-PPEO states; (b) presenting preliminary post-DEC2025 enrollment dynamics (even if only one or two quarters) to confirm that the effect replicates outside the original four states; or (c) constructing placebo DiDs (e.g., pretreatment GA/OH vs. other untreated states) to demonstrate that nothing similar happened prior to PPEO. This would bolster claims that the effect is not an artifact of the specific states chosen.

2. **Account for differential pre-trends and state-specific shocks more flexibly.** While the event study shows no significant pre-trends on average, the standard errors are large, and Figure 2 indicates a lot of volatility in treated states. Consider incorporating state-specific linear (or higher-order) time trends, especially since PPEO states had substantially higher baseline enrollments and may have been on unique trajectories even absent intervention. Alternatively, use matching or synthetic control techniques to pair treated states with similar untreated counterparts (e.g., via enrollment trajectory, demographics) to ensure that the parallel trends assumption holds in a narrower sample.

3. **Deepen the discussion of mechanism with firm-level or owner-level data.** The manifest references detailed ownership information (e.g., private equity, chains). Incorporating this would strengthen the claim that PPEO screened out fraudulent or high-risk ownership types rather than just for-profit forms. For example, compare entry patterns across ownership types within for-profit providers: are the reductions concentrated among private-equity backed firms or those with chains that had prior enforcement actions? Do observed claim denial rates vary by ownership? Even if these analyses are descriptive, they would lend granularity to the mechanism discussion.

4. **Explore potential effects on patient outcomes or Medicare spending.** The paper already mentions spending and quality measures in the abstract and introduction but stops short of causal analysis. If data permit, estimate DiDs for per-beneficiary spending, in-hospital death rates, or hospice utilization days in treated states pre/post-PPEO to assess short-run welfare effects. If these outcomes are unavailable at the same granularity, explain explicitly why and consider using aggregate Medicare spending or hospice utilization at the state level as proxies.

5. **Clarify the sample construction and outcome definitions.** PECOS data can include multiple enrollment records per provider (re-enrollments, ownership changes). How does the paper define a “new enrollment”? Are the counts de-duplicated? Details on how entrant counts handle providers that enroll but do not begin billing would help readers assess measurement error. Additionally, consider supplementing the count outcomes with rates (e.g., new enrollments per 1,000 deaths) to control for population growth or demand changes.

6. **Discuss the general equilibrium implications and heterogeneity.** Entry declines could have downstream supply effects—e.g., increased patient loads at existing hospices, longer wait times, or changes in Medicare spending if patients are diverted to other settings. While measuring these effects may be beyond reach, acknowledging them and, if possible, providing suggestive evidence (for instance, whether hospice census or utilization in neighboring states shifted) would present a more balanced interpretation.

7. **Report more complete inference in tables.** Table 2 and the robustness tables omit p-values for the RI and WCB procedures in some columns, and the event study lacks confidence bands or tests for joint significance. Including p-values or confidence intervals for the few-cluster methods in every relevant table would improve transparency. For the event study, consider plotting the coefficients with bootstrap-inferred bands to visually reassure readers about pre-treatment flatness.

8. **Position the findings within broader hospice policy debates.** The conclusion raises an important policy message, but it would benefit from tying back explicitly to debates over certificate-of-need laws, for-profit regulation, and claims adjudication. How might PPEO interact with other oversight tools? Are there risks of over-deterrence (e.g., delaying legitimate entrants), and if so, how can CMS calibrate PPEO to manage that trade-off? Addressing these questions would help policymakers see how the results fit into a broader strategy.

In sum, the paper addresses a high-stakes policy issue with credible causal tools, but it would benefit from deeper investigation of pre-existing policies, spillovers, and mechanisms, as well as richer contextualization of the implications.
